Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2025-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2024年度独立董事述职报告（章国标）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and shareholder meetings, communication with auditors, and oversight activities during the 2024 fiscal year. The content focuses on the independent director's report on their work and governance oversight rather than financial statements or audit opinions. It is a detailed report on board/management information, specifically the independent director's annual work report. The document length is 4310 characters, which is relatively short but contains substantive content about board activities and director duties, not just an announcement or certification. Therefore, it fits best under Board/Management Information (MANG).
2025-04-29 Chinese
安旭生物第二届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anxu Biotech Co., Ltd. It details the approval of various reports and proposals including the 2024 Annual Report, 2024 Annual Financial Statements, 2024 Profit Distribution Plan, 2024 Fundraising Usage Report, 2025 Audit Firm Reappointment, 2024 Internal Control Evaluation Report, 2024 Asset Impairment Provision, and the 2025 First Quarter Report. The document states that these reports have been reviewed and approved by the Supervisory Board and will be submitted to the 2024 Annual General Meeting for further approval. The document itself does not contain the full financial reports but references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document length is 3765 characters, which is relatively short and mainly serves as an announcement of the Supervisory Board's resolutions regarding these reports and proposals. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and references to other filings rather than the full reports themselves.
2025-04-29 Chinese
安旭生物2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of Hangzhou Anxu Biotechnology Co., Ltd. It contains detailed financial data for the first quarter of 2025, including income, net profit, earnings per share, asset and equity data, and a consolidated balance sheet. The report explicitly states it is unaudited and covers a quarterly period. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and detailed financial content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2025
2025-04-29 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2024年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report on the 2024 annual use and management of raised funds by Hangzhou Anxu Biotechnology Co., Ltd., including specifics on amounts raised, usage, storage, changes in investment projects, and compliance with regulatory requirements. It includes audit opinions from an accounting firm and verification by the sponsoring securities company. The content focuses on the management and use of capital raised through an IPO and subsequent investment projects, with detailed financial figures and regulatory references. This matches the definition of an Audit Report / Information (AR), which covers audit reports, applied accounting principles, and results of internal or regulatory checks related to specific financial activities, but is not a full annual report. The document is lengthy (15,000 characters) and contains substantive financial data and audit opinions, not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-29 Chinese
安旭生物关于2024年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the provision for asset impairment for the fiscal year 2024. It details the amounts of impairment provisions for credit losses, inventory, and intangible assets, with specific figures and explanations. The announcement states that the provision was approved by the board and audit committee and will be submitted to the shareholders' meeting for approval. The document is relatively short (1984 characters) and serves as a formal disclosure of the impairment provision decision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a simple notice of report publication. Given the content and length, this document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about an accounting provision, not a full audit report or annual report itself.
2025-04-29 Chinese
安旭生物关于开展远期结售汇及外汇衍生产品业务的可行性分析报告
Management Reports Classification · 95% confidence The document is titled as a feasibility analysis report regarding the company's plan to conduct forward foreign exchange settlement and foreign exchange derivative business. It discusses the necessity, basic situation, risk management, and conclusion on the feasibility of these financial activities. The content is focused on the company's internal financial risk management and business strategy related to foreign exchange transactions, rather than presenting financial statements, audit results, or regulatory filings. The document length is about 1900 characters, which is relatively short and more of an internal analysis report rather than a formal financial report or announcement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a detailed management report explaining business trends and outlook related to foreign exchange risk management. Therefore, the most appropriate classification is Management Reports (MDA).
2025-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.